DDInter1652 DDInter1248
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease.
Mumps virus strain B level jeryl lynn live antigen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetracosactide
Mumps virus strain B level jeryl lynn live antigen {u} may lead to a major life threatening interaction when taken with {v} Bosutinib
Mumps virus strain B level jeryl lynn live antigen {u} may lead to a major life threatening interaction when taken with {v} Durvalumab
Mumps virus strain B level jeryl lynn live antigen may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Bosutinib
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Durvalumab